CAMBRIDGE, UK—A new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New England Journal of Medicine that circulating tumour DNA is a more powerful marker of breast cancer progression than using blood tests for cancer cells or antigens, and raises the possibility of screening the effectiveness of drugs in days rather than months needed to wait for a change in radiological appearance.
You may also like...
Oncology Times Broadcast News with the Audio Journal of Oncology 11 Nov, 2008 Audio Journal of Oncology in Advance – November 1st, 2006 1 Nov, 2006 Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished? 21 Apr, 2009 Oncology Times Broadcast News with the Audio Journal of Oncology – Bilateral Prophylactic Mastectomy For DCIS 6 Apr, 2009
- Previous story Circulating free tumour DNA test could guide breast cancer therapy
- Next story Two-step immunotherapy brings promise in advanced ovarian cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014